PL376346A1 - Agoniści adrenoreceptora alfa 2B lub 2B/2C do leczenia neurodegeneracji - Google Patents

Agoniści adrenoreceptora alfa 2B lub 2B/2C do leczenia neurodegeneracji

Info

Publication number
PL376346A1
PL376346A1 PL03376346A PL37634603A PL376346A1 PL 376346 A1 PL376346 A1 PL 376346A1 PL 03376346 A PL03376346 A PL 03376346A PL 37634603 A PL37634603 A PL 37634603A PL 376346 A1 PL376346 A1 PL 376346A1
Authority
PL
Poland
Prior art keywords
alpha
neurodegeneration
treatment
adrenoceptor agonists
disease
Prior art date
Application number
PL03376346A
Other languages
English (en)
Other versions
PL216373B1 (pl
Inventor
Larry A. Wheeler
Daniel W. Gil
John E. Donello
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL376346A1 publication Critical patent/PL376346A1/pl
Publication of PL216373B1 publication Critical patent/PL216373B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL376346A 2002-10-08 2003-10-07 Zastosowanie selektywnego agonisty receptora α 2B adrenergicznego lub α 2B/2C adrenergicznego PL216373B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41704902P 2002-10-08 2002-10-08

Publications (2)

Publication Number Publication Date
PL376346A1 true PL376346A1 (pl) 2005-12-27
PL216373B1 PL216373B1 (pl) 2014-03-31

Family

ID=32093954

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376346A PL216373B1 (pl) 2002-10-08 2003-10-07 Zastosowanie selektywnego agonisty receptora α 2B adrenergicznego lub α 2B/2C adrenergicznego

Country Status (19)

Country Link
US (1) US20040138312A1 (pl)
EP (1) EP1549305B1 (pl)
JP (2) JP4724421B2 (pl)
KR (1) KR20050050124A (pl)
CN (1) CN100431536C (pl)
AT (1) ATE429216T1 (pl)
AU (2) AU2003282758A1 (pl)
BR (1) BR0314540A (pl)
CA (1) CA2501347A1 (pl)
DE (1) DE60327335D1 (pl)
ES (1) ES2322954T3 (pl)
IL (1) IL167849A (pl)
MX (1) MXPA05003664A (pl)
NO (1) NO20051663L (pl)
NZ (1) NZ539328A (pl)
PL (1) PL216373B1 (pl)
RU (1) RU2330649C2 (pl)
WO (1) WO2004032913A1 (pl)
ZA (1) ZA200502744B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645678A1 (en) * 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US8455548B2 (en) 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
CA2746295A1 (en) * 2008-12-08 2010-07-08 Allergan, Inc. N-(1-phenyl-2-arylethyl)-4,5-dihydro-3h-pyrrol-2-amine compounds as subtype selective modulators of alpha2b or alpha2b and alpha2c adrenoceptors
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
PL341009A1 (en) * 1997-12-04 2001-03-12 Allergan Sales Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
IL151530A0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Also Published As

Publication number Publication date
ATE429216T1 (de) 2009-05-15
CN1703213A (zh) 2005-11-30
JP2006504739A (ja) 2006-02-09
EP1549305B1 (en) 2009-04-22
PL216373B1 (pl) 2014-03-31
ES2322954T3 (es) 2009-07-02
CN100431536C (zh) 2008-11-12
EP1549305A1 (en) 2005-07-06
AU2009238370A1 (en) 2009-12-17
NZ539328A (en) 2007-01-26
JP2011057700A (ja) 2011-03-24
US20040138312A1 (en) 2004-07-15
AU2003282758A1 (en) 2004-05-04
ZA200502744B (en) 2006-02-22
WO2004032913A1 (en) 2004-04-22
JP4724421B2 (ja) 2011-07-13
CA2501347A1 (en) 2004-04-22
RU2330649C2 (ru) 2008-08-10
HK1081880A1 (zh) 2006-05-26
IL167849A (en) 2011-04-28
KR20050050124A (ko) 2005-05-27
RU2005114504A (ru) 2005-10-27
DE60327335D1 (de) 2009-06-04
AU2009238370B2 (en) 2011-07-21
NO20051663L (no) 2005-05-31
MXPA05003664A (es) 2005-06-08
BR0314540A (pt) 2005-07-26

Similar Documents

Publication Publication Date Title
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
IL175714A0 (en) Quinazolinone compounds as anticancer agents
GB0318447D0 (en) Therapeutic agents
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
IL186200A (en) Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
GB0223038D0 (en) Therapeutic compounds
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
WO2004009590A8 (de) 4-aminosubstituierte pyrimidinderivate
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
WO2004006859A3 (en) Platinum compound
SE0002934D0 (sv) New aporphine esters and in their use in therapy
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
PL376346A1 (pl) Agoniści adrenoreceptora alfa 2B lub 2B/2C do leczenia neurodegeneracji
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
GB9924941D0 (en) Treatment of dyskinesia
ZA200609220B (en) Method of treating dry eye disorders and uveitis